Comparing of Cerus Corporation (CERS) and Kezar Life Sciences Inc. (NASDAQ:KZR)

Both Cerus Corporation (NASDAQ:CERS) and Kezar Life Sciences Inc. (NASDAQ:KZR) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus Corporation 4 0.00 128.27M -0.46 0.00
Kezar Life Sciences Inc. 3 0.00 13.97M -1.36 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Cerus Corporation and Kezar Life Sciences Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Cerus Corporation and Kezar Life Sciences Inc.

Net Margins Return on Equity Return on Assets
Cerus Corporation 2,954,372,711.15% -74.3% -38.3%
Kezar Life Sciences Inc. 463,642,096.18% -23.3% -21.8%

Liquidity

2.8 and 2.5 are the respective Current Ratio and a Quick Ratio of Cerus Corporation. Its rival Kezar Life Sciences Inc.’s Current and Quick Ratios are 21.8 and 21.8 respectively. Kezar Life Sciences Inc. has a better chance of clearing its pay short and long-term debts than Cerus Corporation.

Analyst Ratings

Recommendations and Ratings for Cerus Corporation and Kezar Life Sciences Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerus Corporation 0 0 2 3.00
Kezar Life Sciences Inc. 0 0 1 3.00

Cerus Corporation’s upside potential currently stands at 79.43% and an $7.5 average target price. On the other hand, Kezar Life Sciences Inc.’s potential upside is 449.45% and its average target price is $15. The information presented earlier suggests that Kezar Life Sciences Inc. looks more robust than Cerus Corporation as far as analyst opinion.

Insider & Institutional Ownership

Cerus Corporation and Kezar Life Sciences Inc. has shares held by institutional investors as follows: 69.1% and 52.1%. Cerus Corporation’s share held by insiders are 2.1%. Insiders Comparatively, held 24.72% of Kezar Life Sciences Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerus Corporation 0.17% 8.74% -4.57% 2.27% -18.52% 15.38%
Kezar Life Sciences Inc. -6.01% -20.37% -70.29% -67.29% -63.68% -76.14%

For the past year Cerus Corporation has 15.38% stronger performance while Kezar Life Sciences Inc. has -76.14% weaker performance.

Summary

Cerus Corporation beats Kezar Life Sciences Inc. on 6 of the 10 factors.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.